You are here

Patient Enrollment Goal Achived in Phase 3 Trial of Toremifene, Treatment for Androgen Deprivation Therapy

MEMPHIS, Tenn., Oct. 19 /PRNewswire-FirstCall/ -- GTx, Inc. (NASDAQ:GTXI) , the Men's Health Biotech Company, today announced it has attained its enrollment goal in its pivotal Phase III clinical trial for the use of ACAPODENE (toremifene citrate) 80 mg for the treatment of the serious side effects of androgen deprivation therapy (ADT) for men with advanced prostate cancer.

"More than 1,300 patients in the United States and Mexico are now participating in our Phase III ADT trial. We are on track to have final data from this trial in the second half of 2007," said Mitchell Steiner, MD, CEO of GTx. "Men on ADT are at high risk for developing osteoporosis and life threatening fractures. Studies have shown that average survival is reduced by 39 months in ADT patients who do develop fractures."

Patients in the randomized, double blind, pivotal Phase III ADT study receive daily for two years either an 80 mg tablet of toremifene citrate or placebo. The primary endpoint of the trial is the occurrence of lumbar vertebral fractures. Secondary endpoints include hot flashes, gynecomastia, improvement in lipid profiles, and bone mineral density. GTx is conducting this two year study in accordance with a Special Protocol Assessment (SPA) from the United States Food and Drug Administration.

Later in this quarter, GTx plans to conduct an interim analysis of bone mineral density in the first 200 patients to have completed a full year of treatment in this Phase III trial.

GTx is conducting under a separate SPA another pivotal Phase III trial of ACAPODENE in a 20 mg dose for the prevention of prostate cancer in high risk men who have high grade prostatic intraepithelial neoplasia, or high grade PIN. Under the PIN trial SPA, the timing for the interim efficacy analysis is driven by the rate of prostate cancer events among study patients. GTx expects the interim efficacy analysis will occur within 24 months after completing enrollment of the approximately 1,260 study subjects for the trial. If the interim efficacy analysis reveals a statistically significant reduction in prostate cancer, GTx expects to be able to file the New Drug Application (NDA). GTx will continue to collect efficacy and safety data during the NDA review process. Patient enrollment for the PIN trial began in the first quarter 2005 and is on track to be completed by the first quarter 2006.

Source: GTx, Inc.

Recent Headlines

Record-High Number of Cases in France, Italy, Greece, Other Locations
Will Have a Longer Shelf Life Than Current, Expired Stockpile
Most Women Undergoing Surgery for Suspected Cancer Do Not Have It
Specific Monoclonal Antibodies Ensure Extreme Sensitivity, Accuracy
Almost 64% of Patients Showed Decreased Hemoglobin A1c Levels
Lifesaving Life Foam for Battlefield, Terrorist Attacks, Trauma
Cell Reprogramming Process May Benefit Patients Prone to Severe Hypoglycemia
Beagles Beat Out Advanced Technology